株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の前臨床医薬品開発業務受託機関(CRO)市場の分析と予測:サービスタイプ(バイオアナリシス、薬物代謝・薬物動態、毒性試験)、エンドユーザー、地域別(2014年~2025年)

Preclinical CRO Market Analysis By Service Type (Bioanalysis & DMPK Studies, Toxicology Testing, Other Preclinical Services), By End-use, And Segment Forecasts, 2014 - 2025

発行 Grand View Research, Inc. 商品コード 600832
出版日 ページ情報 英文 94 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.13円で換算しております。
Back to Top
世界の前臨床医薬品開発業務受託機関(CRO)市場の分析と予測:サービスタイプ(バイオアナリシス、薬物代謝・薬物動態、毒性試験)、エンドユーザー、地域別(2014年~2025年) Preclinical CRO Market Analysis By Service Type (Bioanalysis & DMPK Studies, Toxicology Testing, Other Preclinical Services), By End-use, And Segment Forecasts, 2014 - 2025
出版日: 2017年11月15日 ページ情報: 英文 94 Pages
概要

世界の前臨床医薬品開発業務受託機関(CRO)市場は2025年に66億ドルに達すると予測されています。当市場は、早期開発の研究開発費の増加や、アウトソーシングの普及、前臨床段階で使用される薬剤の増加により、予測期間中は着実な成長が見込まれています。また、非臨床毒性試験の成功率は50%で、開発初期段階における医薬品開発業務アウトソーシングの需要に寄与することが期待されています。

当レポートでは、世界の前臨床医薬品開発業務受託機関(CRO)市場について調査し、市場の概要、サービスタイプ・エンドユーザー・地域別の市場動向、市場規模の推移と予測、市場成長要因の分析、市場シェア、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 調査方法と範囲

  • 情報調達
  • データ分析
  • 市場の形成と検証
  • 市場予測のためのアプローチ

第3章 前臨床CRO市場の動向と予測

  • 市場区分と市場範囲
  • 成長要因の分析
  • 浸透と成長の見通しマッピング
  • SWOT分析
  • 産業分析 - ファイブフォース分析

第4章 前臨床CRO市場の動向と予測:サービスタイプ別

  • 市場シェア
  • 市場規模、予測、動向分析:サービスタイプ別
    • バイオアナリシス、薬物代謝 & 薬物動態(DMPR)
    • 毒性試験
    • その他の前臨床サービス

第5章 前臨床CRO市場の動向と予測:エンドユーザー別

  • 市場シェア
  • 市場規模、予測、動向分析:エンドユーザー別
    • バイオ医薬品
    • 政府機関・学術機関
    • 医療機器メーカー

第6章 前臨床CRO市場の動向と予測:地域別

  • 市場動向および市場シェアの分析:地域別
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
  • アジア太平洋地域
    • 日本
    • 中国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
  • 中東・アフリカ地域
    • 南アフリカ
    • サウジアラビア

第7章 競合情勢

  • 戦略の枠組み
  • 企業プロファイル
目次
Product Code: GVR-2-68038-035-4

The global preclinical CRO market is anticipated to reach USD 6.6 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to witness lucrative growth during the forecast period owing to rise in R&D expenditure on early stage development as well as increase in number of drugs in preclinical phase. Hence, increase in outsourcing penetration is further expected to contribute to the growing demand of life science companies for outsourced preclinical services.

Rise in the number of complex drugs entering preclinical trial and growing pressure to curb R&D expenses are expected to contribute to the growing demand for quality CROs, thereby contributing to the market growth. As per Servier Research Institute, issues related to nonclinical toxicology testing results in a 50.0% failure rate in the early stage development phase. High failure rate in this phase is expected to contribute to the demand for early stage development CROs during the forecast period.

Rise in outsourcing of R&D and growing competency of CROs are expected to further contribute to the growing demand for early stage development CROs by life science companies. CRO's such as Charles River Laboratories and LabCorp specialize in early phase development services. Vendors in emerging countries, such as India and China, provide quick preclinical services at lower costs, which contributes to the outsourcing of R&D.

Further Key Findings From the Study Suggest:

  • Toxicology testing held the largest share in the service segment as of 2016 and is expected to dominate over the forecast period. The attrition of drugs due to toxicity is fueling demand for outsourcing of preclinical studies to CROs, which offer end-to-end services, including toxicology testing.
  • Biopharmaceutical companies are the major clients for preclinical vendors and held the highest share in the end-use segment in 2016 and is expected to dominate over the forecast period.
  • North America is expected to dominate preclinical CRO market over the forecast period owing to local presence of established early development CRO's, such as Charles River Laboratories International, Inc.; Laboratory Corporation of America; and Envigo. In addition, better quality of work, established scientific experience, economic stability, and better logistics are other major factors for dominance of the region in the global preclinical trial outsourcing market.
  • Some of the key players in the preclinical CRO market are Charles River Laboratories International, Inc.; Laboratory Corporation of America; Envigo; Eurofins Scientific; PRA Health Science, Inc.; Wuxi AppTec; Medpace, Inc.; Pharmaceutical Product Development, LLC; and Paraxel International Corporation

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot

Chapter 2. Methodology and Scope

  • 2.1. Information Procurement
    • 2.1.1. Purchased database
    • 2.1.2. GVR's internal database
  • 2.2. Data Analysis
  • 2.3. Market Formulation & Validation
  • 2.4. Approaches for Market Estimation
    • 2.4.1. Approach 1: Commodity flow & bottom-up approach
    • 2.4.2. Approach 2: Top-down and parent market analysis

Chapter 3. Preclinical CRO Market Variables, Trends & Scope

  • 3.1. Market Segmentation & Scope
  • 3.2. Market Driver Analysis
  • 3.3. Penetration & Growth Prospect Mapping
  • 3.4. SWOT Analysis, by Factor
    • 3.4.1. Political
    • 3.4.2. Economic
    • 3.4.3. Technological
  • 3.5. Industry Analysis - Porter's

Chapter 4. Preclinical CRO: Service Estimates & Trend Analysis

  • 4.1. Preclinical CRO Market Share, 2016 & 2025
  • 4.2. Market Size, Estimates & Forecasts, and Trend Analyses, 2014 to 2025 for the following products:
    • 4.2.1. Bioanalysis and DMPK studies
      • 4.2.1.1. Bioanalysis and DMPK studies market estimates and forecasts, 2014 to 2025
    • 4.2.2. Toxicology testing
      • 4.2.2.1. Toxicology testing market estimates and forecasts, 2014 to 2025
    • 4.2.3. Other Preclinical services
      • 4.2.3.1. Other preclinical service market estimates and forecasts, 2014 to 2025

Chapter 5. Preclinical CRO: End-Use Estimates & Trend Analysis

  • 5.1. Preclinical CRO Market Share, 2016 & 2025
  • 5.2. Market Size, Estimates & Forecasts and Trend Analyses, 2014 to 2025 for the following end users:
    • 5.2.1. Biopharmaceutical companies
      • 5.2.1.1. Biopharmaceutical companies market estimates and forecasts, 2014 to 2025
    • 5.2.2. Government and academic institutes
      • 5.2.2.1. Government and academic institutes market estimates and forecasts, 2014 to 2025
    • 5.2.3. Medical device companies
      • 5.2.3.1. Medical device companies market estimates and forecasts, 2014 to 2025

Chapter 6. Preclinical CRO: Regional Estimates & Trend Analysis

  • 6.1. Preclinical CRO Regional Movement Analysis & Market Share, 2016 & 2025
  • 6.2. North America
    • 6.2.1. U.S.
      • 6.2.1.1. U.S. revenue estimates and forecasts by, service, 2014 - 2025 (USD Million)
      • 6.2.1.2. U.S. revenue estimates and forecasts by, end use, 2014 - 2025 (USD Million)
    • 6.2.2. Canada
      • 6.2.2.1. Canada revenue estimates and forecasts by, service, 2014 - 2025 (USD Million)
      • 6.2.2.2. Canada revenue estimates and forecasts by, end use, 2014 - 2025 (USD Million)
  • 6.3. Europe
    • 6.3.1. UK
      • 6.3.1.1. UK revenue estimates and forecasts by, service, 2014 - 2025 (USD Million)
      • 6.3.1.2. UK revenue estimates and forecasts by, end use, 2014 - 2025 (USD Million)
    • 6.3.2. Germany
      • 6.3.2.1. Germany revenue estimates and forecasts by, service, 2014 - 2025 (USD Million)
      • 6.3.2.2. Germany revenue estimates and forecasts by, end use, 2014 - 2025 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Japan
      • 6.4.1.1. Japan revenue estimates and forecasts by, service, 2014 - 2025 (USD Million)
      • 6.4.1.2. Japan revenue estimates and forecasts by, end use, 2014 - 2025 (USD Million)
    • 6.4.2. China
      • 6.4.2.1. China revenue estimates and forecasts by, service, 2014 - 2025 (USD Million)
      • 6.4.2.2. China revenue estimates and forecasts by, end use, 2014 - 2025 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Brazil
      • 6.5.1.1. Brazil revenue estimates and forecasts by, service, 2014 - 2025 (USD Million)
      • 6.5.1.2. Brazil revenue estimates and forecasts by, end use, 2014 - 2025 (USD Million)
    • 6.5.2. Mexico
      • 6.5.2.1. Mexico revenue estimates and forecasts by, service, 2014 - 2025 (USD Million)
      • 6.5.2.2. Mexico revenue estimates and forecasts by, end use, 2014 - 2025 (USD Million)
  • 6.6. MEA
    • 6.6.1. South Africa
      • 6.6.1.1. South Africa revenue estimates and forecasts by, service, 2014 - 2025 (USD Million)
      • 6.6.1.2. South Africa revenue estimates and forecasts by, end use, 2014 - 2025 (USD Million)
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Saudi Arabia revenue estimates and forecasts by, service, 2014 - 2025 (USD Million)
      • 6.6.2.2. Saudi Arabia revenue estimates and forecasts by, end use, 2014 - 2025 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Strategy Framework
  • 7.2. Company Profiles
    • 7.2.1. Envigo Corporation.
      • 7.2.1.1. Company Overview
      • 7.2.1.2. Financial Performance
      • 7.2.1.3. Service Benchmarking
      • 7.2.1.4. Strategic Initiatives
    • 7.2.2. MPI research
      • 7.2.2.1. Company Overview
      • 7.2.2.2. Financial Performance
      • 7.2.2.3. Service Benchmarking
      • 7.2.2.4. Strategic Initiatives
    • 7.2.3. Eurofins Scientific
      • 7.2.3.1. Company Overview
      • 7.2.3.2. Financial Performance
      • 7.2.3.3. Service Benchmarking
      • 7.2.3.4. Strategic Initiatives
    • 7.2.4. PRA Health Sciences, Inc
      • 7.2.4.1. Company Overview
      • 7.2.4.2. Financial Performance
      • 7.2.4.3. Service Benchmarking
      • 7.2.4.4. Strategic Initiatives
    • 7.2.5. Wuxi AppTec
      • 7.2.5.1. Company Overview
      • 7.2.5.2. Financial Performance
      • 7.2.5.3. Service Benchmarking
      • 7.2.5.4. Strategic Initiatives
    • 7.2.6. Medpace, Inc.
      • 7.2.6.1. Company Overview
      • 7.2.6.2. Financial Performance
      • 7.2.6.3. Service Benchmarking
      • 7.2.6.4. Strategic Initiatives
    • 7.2.7. Pharmaceutical Product Development (PPD), LLC
      • 7.2.7.1. Company Overview
      • 7.2.7.2. Financial Performance
      • 7.2.7.3. Service Benchmarking
      • 7.2.7.4. Strategic Initiatives
    • 7.2.8. PARAXEL International Corporation
      • 7.2.8.1. Company Overview
      • 7.2.8.2. Financial Performance
      • 7.2.8.3. Service Benchmarking
      • 7.2.8.4. Strategic Initiatives
    • 7.2.9. ICON Plc.
      • 7.2.9.1. Company Overview
      • 7.2.9.2. Financial Performance
      • 7.2.9.3. Service Benchmarking
      • 7.2.9.4. Strategic Initiatives
    • 7.2.10. Laboratory Corporation of America, Inc.
      • 7.2.10.1. Company Overview
      • 7.2.10.2. Financial Performance
      • 7.2.10.3. Service Benchmarking
      • 7.2.10.4. Strategic Initiatives

List of Tables

  • Table 1. Country share estimation
  • Table 2. List of market players
  • Table 3. North America preclinical CRO market, by service, 2014 - 2025 (USD Million)
  • Table 4. North America preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
  • Table 5. U.S. preclinical CRO market, by service, 2014 - 2025 (USD Million)
  • Table 6. U.S. preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
  • Table 7. Canada preclinical CRO market, by service, 2014 - 2025 (USD Million)
  • Table 8. Canada preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
  • Table 9. Europe preclinical CRO market, by service, 2014 - 2025 (USD Million)
  • Table 10. Europe preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
  • Table 11. UK preclinical CRO market, by service, 2014 - 2025 (USD Million)
  • Table 12. UK preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
  • Table 13. Germany preclinical CRO market, by service, 2014 - 2025 (USD Million)
  • Table 14. Germany preclinical CRO market, by end-use, 2014 - 2025 (USD Million))
  • Table 15. Asia Pacific preclinical CRO market, by service, 2014 - 2025 (USD Million)
  • Table 16. Asia Pacific preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
  • Table 17. Japan preclinical CRO market, by service, 2014 - 2025 (USD Million)
  • Table 18. Japan preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
  • Table 19. China preclinical CRO market, by service, 2014 - 2025 (USD Million)
  • Table 20. China preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
  • Table 21. Latin America preclinical CRO market, by service, 2014 - 2025 (USD Million)
  • Table 22. Latin America preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
  • Table 23. Brazil preclinical CRO market, by service, 2014 - 2025 (USD Million)
  • Table 24. Brazil preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
  • Table 25. Mexico preclinical CRO market, by service, 2014 - 2025 (USD Million)
  • Table 26. Mexico preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
  • Table 27. MEA preclinical CRO market, by service, 2014 - 2025 (USD Million)
  • Table 28. MEA preclinical CRO market, by end-use, 2014 - 2025 (USD Million)
  • Table 29. South Africa preclinical CRO market, by service, 2014 - 2025 (USD Million)
  • Table 30. South Africa preclinical CRO market, by end-use, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modeling for market share assessment
  • FIG. 7 Market summary (Figures in USD Million, 2016)
  • FIG. 8 Market trends & outlook
  • FIG. 9 Preclinical CRO market: Market Segmentation
  • FIG. 10 Preclinical CRO market revenue, (USD Million), 2014-2025
  • FIG. 11 Market driver relevance analysis (Current & future impact)
  • FIG. 12 Market restraint relevance analysis (Current & future impact)
  • FIG. 13 Key Opportunities Prioritized
  • FIG. 14 Preclinical CRO Porter's analysis
  • FIG. 15 Preclinical CRO PESTEL analysis
  • FIG. 16 Preclinical CRO market service type outlook key takeaways
  • FIG. 17 Preclinical CRO market: Service Type movement analysis
  • FIG. 18 Bioanalysis and DMPK Studies, 2014 - 2025 (USD Million)
  • FIG. 19 Toxicology testing market, 2014 - 2025 (USD Million)
  • FIG. 20 Other preclinical services market, 2014 - 2025 (USD Million)
  • FIG. 21 Preclinical CRO market end use outlook key takeaways
  • FIG. 22 Preclinical CRO market: End Use Type movement analysis
  • FIG. 23 Biopharmaceutical companies market, 2014 - 2025 (USD Million)
  • FIG. 24 Government and academic institutes market, 2014 - 2025 (USD Million)
  • FIG. 25 Medical device companies market, 2014 - 2025 (USD Million)
  • FIG. 26 Regional market place: Key takeaways
  • FIG. 27 Regional outlook, 2016 & 2025
  • FIG. 28 North America preclinical CRO market, 2014 - 2025 (USD Million)
  • FIG. 29 U.S. preclinical CRO market, 2014 - 2025 (USD Million)
  • FIG. 30 Canada preclinical CRO market, 2014 - 2025 (USD Million)
  • FIG. 31 Europe preclinical CRO market, 2014 - 2025 (USD Million)
  • FIG. 32 UK preclinical CRO market, 2014 - 2025 (USD Million)
  • FIG. 33 Germany preclinical CRO market, 2014 - 2025 (USD Million)
  • FIG. 34 Asia Pacific preclinical CRO market, 2014 - 2025 (USD Million)
  • FIG. 35 Japan preclinical CRO market, 2014 - 2025 (USD Million)
  • FIG. 36 China Preclinical CRO market, 2014 - 2025 (USD Million)
  • FIG. 37 Latin America Preclinical CRO market, 2014 - 2025 (USD Million)
  • FIG. 38 Brazil Preclinical CRO market, 2014 - 2025 (USD Million)
  • FIG. 39 Mexico preclinical CRO market, 2014 - 2025 (USD Million)
  • FIG. 40 MEA preclinical CRO market, 2014 - 2025 (USD Million)
  • FIG. 41 South Africa preclinical CRO market, 2014 - 2025 (USD Million)
  • FIG. 42 Saudi Arabia Preclinical CRO market, 2014 - 2025 (USD Million)
  • FIG. 43 Strategy framework
Back to Top